MongoDB vs. Cloudera: Which Software Stock is a Better Buy?

: MDB | MongoDB, Inc. -  News, Ratings, and Charts

MDB – As the economy becomes more digitized, the demand for software solutions will continue to rise. That’s why software stocks are often on the minds of investors. MongoDB (MDB) and Cloudera (CLDR) are two lesser known names, but still worth a look. Read more to find out which is the better stock.

There is a somewhat respectable argument that there is never a bad time to buy software stocks. Software has become ubiquitous and will continue to shape how companies do business, how educators teach, and how nearly every other facet of the economy functions.

Economic growth is poised to explode following the reopening of the global economy. The late summer and early fall of 2021 might be one of the best times to own software stocks.

The rising economic tide will lift the majority of the boats, including the always-popular software stocks. MongoDB (MDB) and Cloudera (CLDR) are two software stocks with the potential to move to new heights in the ensuing months. But which is a better buy?

MongoDB (MDB)

Businesses and governments use MDB’s database platform. Headquartered in New York City, MDB serves clients in the media, healthcare, financial services, retail, entertainment, and government sectors. MDB is priced at $498.12. The stock’s 52-week high is $515, while its 52-week low is $200.50.

MDB is a POWR Ratings disappointment with an overall grade of D, translating into a Sell rating in our POWR Ratings system. The stock has D grades in the Value and Stability components and C grades in the Growth and Sentiment components. Click here to find out how MDB grades in the additional components, including Momentum and Quality.

Out of the 147 stocks in the Software – Application industry, MDB is ranked 127th. You can find the top stocks in this industry by clicking here. MDB’s latest strong earnings report revealed revenue growth accelerated in the second quarter. In fact, the stock jumped more than 25% following the earnings release. MDB’s top line expanded 44% on a year-over-year basis, coming just shy of $200 million. 

MDB’s customer count increased by more than 2,000 in the quarter. The company’s Atlas cloud database helped spike revenue by more than 80% on a year-over-year basis. Take a look at the analysts’ predictions for MDB, and you will find the average target price is $394.39. MDB is currently trading at $498.15, which indicates that analysts believe that MDB is currently overvalued.

Click here to check out our Software Industry Report for 2021

Cloudera (CLDR)

CLDR makes and distributes software designed for business data. This software includes applications for everything from data storage to data management, analysis, processing, and more. CLDR is currently trading at $15.95. The stock’s 52-week high is $19.35, while its 52-week low is $9.34.

CLDR is amid a takeover at a value that is only slightly higher than its price when it went public. The sale came on the heels of the company’s $163 million loss last year. The company lost $187 the year before that. Though CLDR’s transition to subscription-based service through the cloud will likely prove prudent, the company will be sold to Clayton, Dubilier & Rice, assuming the deal closes later this year.

CLDR has an overall grade of B and a Buy rating in the POWR Ratings system. The stock has B grades in the Quality and Growth components. Click here to find out how CLDR grades in the rest of the components, including Value, Momentum, Stability, and Sentiment. 

Of the 60 stocks in the Software – Business industry, CLDR is ranked 10th. Investors can find the top stocks in this industry by clicking here. In the previous 165 days, CLDR’s average upside potential calculated by analyst estimates has been an impressive 26.7%.

Which is the Better Buy?

CLDR is the better of these two software stocks. CLDR’s top-10 ranking in its industry combined with its Buy rating in the POWR Ratings make it a strong software stock. 


MDB shares were trading at $471.78 per share on Thursday morning, up $0.04 (+0.01%). Year-to-date, MDB has gained 31.40%, versus a 21.67% rise in the benchmark S&P 500 index during the same period.


About the Author: Patrick Ryan


Patrick Ryan has more than a dozen years of investing experience with a focus on information technology, consumer and entertainment sectors. In addition to working for StockNews, Patrick has also written for Wealth Authority and Fallon Wealth Management. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MDBGet RatingGet RatingGet Rating
CLDRGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

2 Best Stocks of All Time!

This bear market has me thinking back to my 2 best trades of all time. That being when I bought Amazon (AMZN) and Booking (BKNG) back in 2001 as they were tumbling down in the midst of a bear market...but now enjoying truly phenomenal gains. Let’s discuss what those investments had in common and how that will help us find more big winners in the years ahead. Read on below for more...

:  |  News, Ratings, and Charts

Bears Back in Charge...What Happens Next?

A month ago the bulls were claiming victory as they created a charge back over 4,000 for the S&P 500 (SPY). Since then that false narrative has been peeled away and investors are more honestly looking at the bleak outlook formed by high inflation and a hawkish Fed. That explains why we are back retesting the June lows. Now we have to ponder what comes next and how to trade our way to profits. Read on below for the full story...

:  |  News, Ratings, and Charts

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK), and Bristol-Myers Squibb (BMY), which are currently trading under $100. Read on…

:  |  News, Ratings, and Charts

Cut These 2 Stocks From Your Portfolio Right Now

The Fed succeeding in a ‘soft landing’ seems unlikely. Analysts are expecting a recession soon. So, with the rising odds of the Fed raising rates aggressively, it could be wise to steer clear of fundamentally weak stocks Roblox (RBLX) and Affirm Holdings (AFRM). Read on…

:  |  News, Ratings, and Charts

3 Healthcare Stocks Under $100 to Buy Right Now

The rising prevalence of chronic diseases and the aging population are major growth drivers for the healthcare industry. In addition, increased investments in technological advancements should further bolster the industry’s growth. Thus, we think it may be prudent to buy quality healthcare stocks Pfizer Inc. (PFE), Merck & Co. (MRK), and Bristol-Myers Squibb (BMY), which are currently trading under $100. Read on…

Read More Stories

More MongoDB, Inc. - (MDB) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MDB News